Ma, Mark H <br/><br/>
The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Mar 2003 
 - 1136-44 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1078-0432 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Active Transport, Cell Nucleus<br/>Adenoviridae--genetics<br/>Antineoplastic Agents--pharmacology<br/>Apoptosis<br/>Blotting, Western<br/>Boronic Acids--pharmacology<br/>Bortezomib<br/>Cell Division<br/>Cell Nucleus--metabolism<br/>Cell Survival<br/>Cysteine Endopeptidases<br/>Cytosol--metabolism<br/>Dose-Response Relationship, Drug<br/>Genes, Dominant<br/>Humans<br/>I-kappa B Proteins--metabolism<br/>Melphalan--pharmacology<br/>Microscopy, Fluorescence<br/>Multienzyme Complexes--antagonists & inhibitors<br/>Multiple Myeloma--metabolism<br/>NF-KappaB Inhibitor alpha<br/>NF-kappa B--metabolism<br/>Phosphorylation<br/>Proteasome Endopeptidase Complex<br/>Pyrazines--pharmacology<br/>Tetrazolium Salts--pharmacology<br/>Thiazoles--pharmacology<br/>Time Factors<br/>Transfection<br/>Tumor Cells, Cultured<br/>Ubiquitin--metabolism